Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Collegium Pharmaceutical, Inc. COLL

Healthcare  —  Drug Manufacturers Specialty & Generic
22.53 (0.11) (0.49%) as of 25 Sep
Market cap
$737.1M
P/E
14.7×
Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Collegium Pharmaceutical, Inc. (COLL) Business Profile

Updated before January 2025

Company Overview

Collegium Pharmaceutical, Inc. (COLL) is a specialty pharmaceutical company focused on developing and commercializing innovative medicines for pain management and other therapeutic areas. Founded in 2002 and headquartered in Stoughton, Massachusetts, the company has established itself as a leader in the development of abuse-deterrent formulations of opioid medications. Collegium’s mission is to responsibly address the needs of patients suffering from chronic pain while minimizing the risks associated with opioid misuse and abuse.

The company is led by a team of experienced professionals in the pharmaceutical industry. As of the latest updates, the key leadership includes J. David Stack, who serves as Chairman, President, and Chief Executive Officer. Under his leadership, Collegium has grown significantly, focusing on innovation, patient safety, and regulatory compliance.

Core Business Segments

Collegium Pharmaceutical operates primarily in the pain management sector, with a focus on opioid medications that incorporate abuse-deterrent technologies. The company’s core business segments include:

1. Pain Management Products

  • Xtampza ER: Collegium’s flagship product, Xtampza ER, is an extended-release, abuse-deterrent formulation of oxycodone. It is designed to provide effective pain relief while reducing the potential for misuse and abuse. Xtampza ER is a critical component of Collegium’s portfolio and has gained significant traction in the market.
  • Nucynta Franchise: Collegium acquired the U.S. rights to the Nucynta product line, which includes Nucynta ER (extended-release) and Nucynta IR (immediate-release). These products are used for the management of moderate to severe pain and diabetic peripheral neuropathy.

2. Abuse-Deterrent Technologies

Collegium is a pioneer in the development of abuse-deterrent formulations. The company’s proprietary DETERx® technology platform is designed to prevent common methods of abuse, such as crushing, snorting, or injecting opioid medications. This technology is integrated into Xtampza ER and serves as a foundation for future product development.

3. Support Services

To complement its product offerings, Collegium provides patient support programs and educational resources for healthcare providers. These services aim to improve patient outcomes and ensure the responsible use of opioid medications.

Business Model

Collegium Pharmaceutical’s business model revolves around the development, commercialization, and distribution of innovative pain management solutions. The company generates revenue primarily through the sale of its branded products, such as Xtampza ER and the Nucynta franchise. Collegium’s approach includes:

  • Research and Development (R&D): Investing in the development of new abuse-deterrent formulations and expanding the applications of its DETERx® technology.
  • Strategic Partnerships: Collaborating with healthcare providers, payers, and distributors to ensure broad access to its products.
  • Market Expansion: Focusing on increasing market share through targeted marketing efforts and educational initiatives.

Strategic Direction

Collegium Pharmaceutical is committed to addressing the opioid crisis by providing safer alternatives for pain management. The company’s strategic priorities include:

  • Product Portfolio Expansion: Developing new abuse-deterrent formulations and exploring opportunities in adjacent therapeutic areas.
  • Sustainability Goals: Implementing environmentally responsible practices in manufacturing and distribution.
  • Geographic Expansion: Exploring opportunities to expand its presence in international markets.
  • Digital Transformation: Leveraging technology to enhance patient support services and improve operational efficiency.

Competitive Landscape

Collegium Pharmaceutical operates in a highly competitive market, facing competition from both branded and generic pharmaceutical companies. Key competitors include:

  • Purdue Pharma: Known for its OxyContin product, Purdue Pharma is a major player in the opioid market.
  • Teva Pharmaceuticals: A global leader in generic and specialty medicines, including pain management products.
  • Endo International: Offers a range of pain management solutions, including abuse-deterrent formulations.
  • Mallinckrodt Pharmaceuticals: Specializes in pain management and other therapeutic areas.

Despite the competition, Collegium differentiates itself through its focus on abuse-deterrent technologies and commitment to patient safety.

Risk Factors

Collegium Pharmaceutical faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: The opioid market is heavily regulated, and changes in policies or guidelines could affect Collegium’s products.
  • Market Dependence: A significant portion of the company’s revenue comes from Xtampza ER and the Nucynta franchise, making it vulnerable to market fluctuations.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers poses a risk of supply chain interruptions.
  • Litigation Risks: The opioid crisis has led to increased litigation against pharmaceutical companies, which could impact Collegium.

Recent Developments

Collegium Pharmaceutical has made significant strides in recent years, including:

  • Acquisition of Nucynta Franchise: The acquisition has strengthened Collegium’s position in the pain management market.
  • Regulatory Approvals: Xtampza ER has received approval for expanded labeling, highlighting its abuse-deterrent properties.
  • Corporate Initiatives: The company has launched new patient support programs and educational campaigns to promote the responsible use of opioids.

Global developments, such as the COVID-19 pandemic, have also impacted Collegium’s operations, leading to increased focus on digital engagement and supply chain resilience.

Investment Considerations

Investors considering Collegium Pharmaceutical should weigh the following factors:

Strengths

  • Innovative Products: Collegium’s focus on abuse-deterrent technologies sets it apart in the opioid market.
  • Strong Market Position: The company’s flagship products, Xtampza ER and Nucynta, have established a solid market presence.
  • Growth Potential: Collegium’s strategic initiatives and commitment to innovation position it for long-term growth.

Risks

  • Regulatory and Legal Risks: The opioid crisis has led to increased scrutiny and litigation, which could impact Collegium.
  • Market Dependence: Reliance on a few key products poses a risk to revenue stability.
  • Competitive Pressure: The pharmaceutical industry is highly competitive, with numerous players vying for market share.

Conclusion

Collegium Pharmaceutical, Inc. is a leader in the development of abuse-deterrent opioid medications, addressing a critical need in the pain management market. With a strong product portfolio, innovative technologies, and a commitment to patient safety, Collegium is well-positioned for future growth. However, investors should carefully consider the regulatory and market risks associated with the opioid industry. Overall, Collegium’s focus on innovation and responsible pain management makes it a compelling player in the pharmaceutical sector.